Our global list of drug combinations
The following is a list of products listed by our company, which is only for medical professionals to refer to.
TPIAO （Recombinant human thrombopoietin (rhTPO))
In 2005, TPIAO was listed and has been approved by the NMPA for two indications that are the treatment of chemotherapy-induced thrombopenia (approved in 2005) and immune thrombocytopenia (ITP) (approved in 2010), which is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.
| Indication | Manufacturing base | Dosage form & Dosage |
|
Treatment for chemotherapy-induced thrombocytopenia (CIT); |
Shenyang manufacturing base |
7500 U/1 ml; 15000 U/1 ml |
Cipterbin （Inetetamab for Injection)
Cipterbin was formally approved in June 2020 as the first innovative anti-HER2 monoclonal antibody in China with the engineered Fc region, optimized production process and a stronger ADCC effect. Research showed that in combination with chemotherapy drugs, it can significantly reduce the risk of disease progression in patients with HER2-positive metastatic breast cancer, improve the objective response rate, and prolong the progression-free survival of the patients.
| Indication | Manufacturing base | Dosage form & Dosage |
| This product is indicated, in combination with vinorelbine, for the treatment of patients with HER2-positive metastatic breast cancer, who have received one or more chemotherapy regimens. | Shanghai manufacturing base | 50mg/bottle |
Intefen （Human Interferon α2a for Injection)
In April 1995, Intefen was approved to be manufactured by NMPA.In December 1995, Intefen was launched and is included in the National Medical Insurance Catalogue as a Category B drug.
| Indication | Manufacturing base | Dosage form & Dosage |
| Treatment of lymphatic or hematopoietic malignancies and viral infections: adult chronic hepatitis B, acute and chronic hepatitis C and condyloma acuminata. | Shenyang manufacturing base |
Injection - 1,000,000 IU/ml, 3,000,000 IU/ml, 5,000,000 IU/ml; Freeze-dried powder - 1,000,000 IU/ml, 3,000,000 IU/ml, 5,000,000 IU/ml. |
Inleusin （Human Interleukin-2 for Injection)
In June 1995, NMPA production approval documents were obtained for Inleusin. This product was launched in March 1996 and is included in the National Medical Insurance Catalogue as a Category B drug.
| Indication | Manufacturing base | Dosage form & Dosage |
| Treatment of renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis. | Shenyang manufacturing base | 100,000 IU/bottle; 200,000 IU/bottle; 500,000 IU/bottle; 1,000,000 IU/bottle |